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1. Introduction 
The management of occult cervical lymph node metastasis in well-differentiated thyroid 
cancer (WDTC) is controversial. Given the risks of hypocalcemia, recurrent laryngeal nerve 
injury, and increased operative time with a central compartment neck dissection (CCND), a 
routine adoption of prophylactic lymph node dissection has not been accepted by many as a 
standard management for occult metastasis (Henry et al., 1998; Pereira et al., 2005; Shen et 
al., 2010).  Conversely, other thyroid surgeons feel that the complication rate is low and that 
the benefits of CCND outweigh the risks (Anand et al., 2009; Haigh et al., 2000; Keleman et 
al., 1998; Pelizzo et al., 2001; Pitman et al., 2003; Rettenbacher et al., 2000). As a result, 
sentinel lymph node biopsy (SLNB) has gained an increase in popularity in recent years.  
The principle of SLNB and its historical rise in other fields will be the starting point of the 
chapter. The SLN is defined as the first lymph node in a regional lymphatic basin receiving 
lymph flow from a primary tumor. For the past nineteen years, SLNB has been an 
acceptable technique for identifying the presence of metastatic disease for cutaneous 
melanoma (Morton et al., 1992) and early breast cancer (Giuliano et al., 1994; Krag et al., 
1993). Lymphatic mapping with SLN permits staging of malignant tumors in an effort to 
avoid complete nodal dissection and its associated morbidity.  The ideology behind SLN 
surgery follows the concept that the sentinel node is predictive of a primary tumor that has 
the potential to metastasize.  If the sentinel node is positive, the pathological status of 
additional lymph nodes may be positive as well. Recently, SLNB techniques have been 
proposed for other tumor types, including lung, gastrointestinal and gynecologic 
malignancies (Makar et al., 2001), squamous cell carcinoma of the head and neck (Pitman et 
al., 2003; Taylor et al., 2001), colorectal cancer (Saha et al., 2000) and thyroid cancer (Pelizzo 
et al., 2001; Dixon et al., 2000).  
To understand the applicability of SLNB in thyroid cancer, the cervical lymphatic 
anatomy will be reviewed. The mechanism of lymphatic tumoral spread in thyroid cancer 
and the clinical significance of such lymph node metastases will then be discussed.  The 
arguments in favor and against prophylactic CCND will follow thereby providing the 
context in which the idea of the SLNB shows its advantages in the management of WDTC. 
The benefits of SLNB over a formal CCND will be discussed in the chapter with emphasis 
on the major advantages such as a decreased risk of hypocalcemia, decreased risk to the 
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recurrent laryngeal nerve (RLN) injury and decreased operative time. Different 
techniques of SLN biopsy will then be outlined and our detailed institutional protocol, the 
McGill Thyroid Injection Protocol, will be illustrated. A comprehensive review of the 
literature on the outcomes of SLNB in the approach to management of thyroid cancer will 
then follow. Our chapter will conclude by addressing the pitfalls of SLNB in WDTC 
including the potential causes of false-negative cases in addition to adverse events related 
to the procedure. 
2. Sentinel lymph node biopsy, a tool for the surgeon 
In the field of oncology, lymph node status is one of the most important prognostic factors 
and a key element of tumor staging. It is also a guide towards the appropriate therapy and 
overall a crucial component in the assessment of patients with cancer. The approach to 
management of metastatic lymph nodes goes from medical management to various degrees 
of surgical aggressiveness.  
2.1 The principle 
In 1960, Gould (Gould et al.,1960) was the first to introduce the concept of the sentinel 
lymph node. According to him, lymphatic flow is unidirectional, and there is orderly 
progression of cancer cells from the primary organ to the first lymph node in the chain 
before spreading to other regional lymph nodes. This first lymph node draining a regional 
lymphatic basin from a primary tumor is defined as the sentinel lymph node, and its 
histological status is thought to be representative of the status of the other nodes in the 
chain. The SLNB technique finds its place where formal lymph node dissection is associated 
with significant morbidity, such as the groin or axilla.  
2.2 The history 
In 1992, the technique for lymphatic mapping was first described by Morton (Morton et al., 
1992) in patients with cutaneous malignancy, and was found to be not only simple and 
practical, but also reliable with a reported false-negative rate of less than 1%. This report 
introduced modern surgical oncologists to a new surgical technique with a wide range of 
applications. Subsequently, Giuliano (Giuliano et al., 1994) exported the technique to breast 
cancer and demonstrated a reliable identification of SLN using a vital blue dye.  In the last 
two decades, SLNB has been validated as an accurate method for assessing lymph node 
status and has gained consensus as the standard of management for identifying regional 
lymphatic spread in melanoma and breast cancer. The use of this technique in the 
management algorithms is under investigations for other solid cancer including thyroid.  
3. Cervical lymph nodes in thyroid cancer  
3.1 The anatomy 
There are 500 lymph nodes in the body and 200 of these are in the head and neck region 
(Grodski et al., 2007). Historically, the location of cervical lymphadenopathies has been 
described in terms of chains and triangles, but currently, the most used system of nodal 
mapping anatomically classifies lymph nodes into levels (Sakorafas et al., 2010). 
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Fig. 1. Cervical lymph node levels (from Rugiero, 2008) 
Level I is bound by the body of the mandible superiorly, stylohyoid muscle posteriorly, and 
the anterior belly of the digastric muscle on the contralateral side anteriorly. This level may 
be divided into level Ia, which refers to the nodes in the submental triangle (bound by the 
anterior bellies of the digastric muscles and the hyoid bone), and Ib, which refers to the 
submandibular triangle nodes. 
Level II lymph nodes are related to the upper third of the jugular vein, extending from the 
skull base to the inferior border of the hyoid bone. The anterior border of level II is the 
stylohyoid muscle, and the posterior border is the posterior border of the 
sternocleidomastoid muscle. The spinal accessory nerve, which travels obliquely across this 
area, is used as a landmark to subdivide this group into IIb, the portion above and behind 
the nerve, and IIa, the part that lies anteroinferiorly and closer to the internal jugular vein. 
Level III nodes are located between the hyoid superiorly and a horizontal plane defined by 
the inferior border of the cricoid cartilage. The sternohyoid muscle marks the anterior limit 
of level III, and the posterior border of the sternocleidomastoid muscle is the posterior 
border. 
Level IV refers to the group of nodes related to the lower third of the jugular vein. These 
nodes are located between the inferior border of the cricoid cartilage and the clavicle, and, 
like level III, the anterior boundary is the sternohyoid muscle, and the posterior border is 
the posterior border of the sternocleidomastoid muscle. 
Level V refers to the lymph nodes located in the posterior triangle of the neck. These include 
the spinal accessory, transverse cervical, and supraclavicular group of nodes. Level V is 
bound anteriorly by the posterior border of the sternocleidomastoid muscle and posteriorly 
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by the anterior border of the trapezius muscle. Level V extends from the apex of the 
convergence of the sternocleidomastoid and trapezius muscle superiorly to the clavicle 
inferiorly as shown below. This level is subdivided by a plane defined by the inferior border 
of the cricoid cartilage into level Va superiorly and level Vb inferiorly. 
Level VI refers to lymph nodes of the anterior, or central, compartment of the neck. Defined 
by the carotid arteries laterally, the hyoid bone superiorly, and the suprasternal notch 
inferiorly, it is rich in lymphatics that drain the thyroid gland, subglottic larynx, cervical 
trachea, hypopharynx, and cervical esophagus. Lymph nodes in this compartment are 
located in the tracheoesophageal groove (paratracheal nodes), in front of the trachea 
(pretracheal nodes), around the thyroid gland (parathyroidal nodes), and on the 
cricothyroid membrane (precricoid or Delphian node) (Rugiero, 2008). 
The thyroid gland contains a dense network of intrathyroidal lymphatics with 
communication across the isthmus. Lymphatic flow tends to be to the ipsilateral level VI 
lymph nodes primarily since thyroid lymphatics usually accompany a venous drainage 
pattern into the central compartment of the neck (Roh & Kock, 2010). The upper poles, along 
with the pyramidal lobe and isthmus also drain superiorly toward lymph node levels II/III 
while the lateral aspect of each lobe drain towards lymph node levels III/IV. The lower pole 
of the gland drains initially into level VI then goes on to levels IV and VII (Roh & Koch, 
2010; Sakorafas et al., 2010).  
3.2 Lymph nodes metastases in well-differentiated thyroid cancer  
Papillary thyroid cancer (PTC) is the most common thyroid malignancy. It represents 75% of 
thyroid malignancies and 90% of WDTC. It spreads predominantly via the lymphatics to the 
local draining lymph nodes (Balasubramanian & Harrison, 2011). It is generally believed that 
the central cervical compartment is the primary zone of lymphatic involvement for all thyroid 
cancers except those located in the upper pole of the glands from which lymphatic drainage 
may flow directly into the lateral neck nodes (Henry et al., 1998). In keeping with the theory, 
Nogychi in a study of 68 patients after elective neck dissection, found 78% of nodal metastases 
in the paratracheal region and 22% in the jugular chain (Nogychi et al., 1987, as cited in 
Kelemen et al., 1998). Many groups have, however, reported that the risk of lymphatic 
metastases was greatest for the lateral nodal groups (level II, III and IV) (Caron et al., 2006; 
Gimm et al., 1998; Lee et al., 2008; Roh et al., 2007, 2008; Shah et al., 1990) while others have 
shown comparable rates of involvements in both the central cervical and lateral neck 
compartments (Machens et al., 2002). 
Irrespective of location, lymph node metastases are a common finding in PTC and tend to 
occur relatively early. The incidence of lymph node metastases has been reported to be as 
high as 90% and the incidence of palpable disease ranges between 30-50% (Dixon et al., 2000; 
Grodski et al., 2007). Histological evidence of nodal metastases in patients with clinically 
node negative PTC is approximately 50% (Balasubramanian & Harrison, 2011), but rates 
anywhere between 25 to 90% have been reported in studies where elective neck dissections 
were performed on patients without suspicious lymphadenopathies (Cunningham et al., 
2010). Interestingly, in a similar group of patients who were observed and did not undergo a 
neck dissection, the rate of recurrence was only 1.4%, thus questioning the clinical 
significance of such lymph node metastases (Kelemen et al., 1998). 
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3.3 Clinical significance of lymph nodes metastases  
Most clinical trials confirm that regional nodes are usually the first site of recurrence 
(Kelemen et al., 1998).  In fact, metastases to lymph nodes account for 75% of locoregional 
recurrence (Grodski et al., 2007). It is estimated that the risk for nodal recurrence is 30% to 
50% during 10 years. The overall recurrence rate has been documented at 20%, with most of 
them discovered within 24 months. Of these, 70% are detected through a radioactive iodine 
whole body scan with only 40% being clinically apparent (Kelemen et al., 1998).  
In a series of patients with nodal metastases and a final histological diagnosis of papillary, 
follicular, or Hürthle cell carcinoma, a recurrence rate of 19% has been recorded vs 2% in 
patients free of nodal disease (Kelemen et al., 1998). In an age-matched study of patients with 
differentiated thyroid cancer, recurrences were also more common among patients with nodal 
involvement (32 vs. 14%) (Grodski et al., 2007). The presence of central node metastases in the 
lymphadenectomy specimen is therefore an independent predictor of disease free survival but 
its actual significance on the overall prognosis remains controversial. 
Although PTC lymph node metastases are reported by some to have no clinically important 
effect on outcome in low risk patients, a study among 9904 patients with PTC has found that 
lymph node metastases, along with other factors, predicted poor outcome on multivariate 
analysis (Podnos et al., 2005). All-cause survival at 14 years was 82% for PTC without lymph 
node and 79% with lymph node metastases (p < 0.05). Another recent study showed that 
lymph node involvement is an independent risk factor for decreased survival, but only in 
patients with follicular carcinoma and patients with papillary carcinoma over age 45 years 
(Zaydfudim et al., 2008). Multiple metastases and extracapsular nodal extension are other 
factors increasing the risk of regional recurrence (Leboulleux et al., 2005). However, in an 
analysis of 5123 patients over a 30-year period, even when corrected for TNM staging, a 
significantly higher mortality rate for patients with lymph node involvement has been 
shown (Grodski et al., 2007). 
Despite these data, PTC has an excellent prognosis, but there is no doubt that lymphatic 
spread is associated with increased risk of loco-regional recurrence which may require an 
additional and more complicated surgery, overall significantly affecting patients’ quality of 
life not only through the major psychological impact of cancer recurrence, but also through 
increased rates of all complications of exploration of scarred necks (Kelemen et al., 1998). We 
are therefore assisting to a paradigm shift in the aims of treatment of PTC, from a focus on 
survival to a focus of disease-free status as a valid endpoint to evaluate the effectiveness of 
therapy. 
3.4 Cervical neck dissection in well-differentiated thyroid cancer 
While few would argue against a formal therapeutic neck dissection in cases of macroscopic 
clinically apparent lymph node metastases in patients with WDTC, there is great 
heterogeneity in the surgical approaches to a clinically negative neck. Recommendations in 
the management of adenopathy associated with PTC are quite varied and include blind 
nodal sampling, central compartment neck dissection, and modified radical neck dissection 
(Anand et al., 2009). To eliminate the probability of leaving behind residual disease, routine 
total thyroidectomy with cervical lymph node dissection (CLND) would be theoretically the 
ideal operation. However, such an aggressive surgical approach will represent over-
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treatment in a large percentage of patients, associated with longer surgical time and an 
unjustified increase of surgical morbidity (Sakorafas et al., 2010). Balancing the risk of 
increased morbidity from CLND with the benefit of removing a source of potential 
recurrence creates a controversial and difficult management decision. To help in the 
decision making process, guidelines for prophylactic CLND have been issued by different 
associations. Unfortunately, they remain vague and unclear with a certain degree of 
antagonistic recommendations. 
3.4.1 In favor of prophylactic cervical lymph node dissection 
Because of the high rate of occult lymph node metastases, their association with more 
frequent tumor recurrence and our inability to adequately indentify these cases pre-
operatively, some experts argue in favor of routine prophylactic CLND in cases of WDTC. 
The British Thyroid Association (BTA) and the American Thyroid Association (ATA) are 
proponents of the prophylactic CLND (BTA, 2007; Cooper et al., 2009), especially in patients 
considered high risk. They maintain that the potential increased morbidity is small in 
experienced hands and hence a strong argument can be made for routine central CLND in 
all patients with WDTC and no known preoperative or intraoperative evidence of node 
involvement. More specifically, the ATA recommends prophylactic central neck dissection 
for patients with clinically uninvolved lymph nodes, especially for advanced tumors (T3 
and T4 disease), and asserts that the central CLND may be appropriately omitted for T1 and 
T2 papillary and follicular thyroid cancers. They also acknowledge that omitting CLND for 
these smaller tumors, ‘‘may increase the chance of locoregional recurrence, but overall may 
be safer in less experienced surgical hands,’’ to avoid the associated morbidity. This 
approach to microscopic nodal disease may result in fewer postoperative complications than 
routine dissection, but may fail to detect lymph node metastases in patients with smaller 
tumors, and may subject patients with larger tumors who do not have lymph node 
metastases to unnecessary lymph node resection. In addition, the guidelines allow for 
interpretation of these recommendations in the light of available surgical expertise at each 
institution, so that more invasive approaches are only recommended if experienced 
surgeons are available to carry them out, which is yet another factor contributing to the 
great variability in management. 
Besides lower recurrence rates, prophylactic CLND has also the advantage of adequate 
staging, enhancing the effects of radioactive iodine by removing potentially positive lymph 
nodes while also lowering the postoperative thyroglobulin levels thereby facilitating follow-
up (Grodski et al., 2007; Sakorafas et al., 2010). 
In the discussion about the extent of prophylactic CLND in PTC, it should be remembered 
that the impact of the central compartment recurrence differs from that of a lateral 
compartment. It is generally accepted that lymph node metastases in the visceral 
compartment of the neck have greater clinical importance than metastases in the lateral neck 
areas (Henry et al., 1998). Reoperation for recurrence in the lateral compartment can be 
performed more easily than that for recurrence in the central compartment, where more 
critical structures (i.e., trachea, great vessels, etc) are located. Therefore, since metastases in 
the central compartment are very common, recurrences in the area are sometimes difficult to 
demonstrate, especially in males with a short and thick neck (Henry et al., 1998) and given 
that surgery for recurrence in the central compartment may be a complicated procedure, 
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prophylactic central CLND during the initial thyroid surgery (usually through the same 
incision) seems for many to be a reasonable management option (Sakorafas et al., 2010). 
3.4.2 Against prophylactic cervical lymph node dissection 
The American Association of Clinical Endocrinology, the American Association of 
Endocrine Surgeons (Cobin et al., 2001) and the NCCN do not recommend routine central 
CLND, particularly in low-risk patients with PTC. The argument against prophylactic 
CLND resides in the added complications associated with the procedure. The possible 
complications of central compartment neck dissection include hypoparathyroidism, injury 
to the recurrent and superior laryngeal nerves, hemorrhage and seroma (Sakorafas et al., 
2010). The morbidity of prophylactic central neck dissection was evaluated in a study of 100 
patients who underwent total thyroidectomy of which 50 patients with papillary thyroid 
cancer and no evidence of macroscopic metastases also had a prophylactic central neck 
dissection (Henry et al., 1998). In the group that had no neck dissection, there was no 
permanent hypoparathyroidism, but there were four cases of transient hypoparathyroidism 
(8%). In the group that underwent the prophylactic procedure, seven patients presented 
transient hypoparathyroidism (14%) and two patients (4%) remained with permanent 
hypoparathyroidism. The authors were also able to conclude that after total thyroidectomy 
for PTC, prophylactic central neck dissection does not increase recurrent laryngeal nerve 
morbidity but is responsible for a higher rate of hypoparathyroidism, especially in the early 
postoperative course (Henry et al., 1998). They attributed the hypoparathyroidism 
associated with neck dissection to the insufficiency of blood supply generated by the 
dissection. Similar rates of permanent hypoparathyroidism were also reported by Pereira 
(Pereira et al., 2005) (4.6%) with the extent of hypocalcemia correlating with the extent of 
surgery. A recent study by Mitra convincingly showed that total thyroidectomy combined 
with CCND led to a marked increase in both transient as well as permanent hypocalcemia 
(Mitra et al., 2011). These authors therefore concluded that the morbidity of bilateral cervical 
neck dissections is significant, and cautioned against the systematic implementation of this 
technique in the absence of gross nodal involvement.  
Another factor contributing to the opposition towards routine lymph node dissection is the 
questionable usefulness of the procedure in preventing recurrence. Recent data has not 
demonstrated any therapeutic gain in achieving a significant reduction in local recurrence 
by adding CCND to total thyroidectomy (Zetoune et al., 2010). Despite the high frequency 
of microscopic lymph node metastases, the recurrence rate in patients with occult nodal 
disease who have not undergone nodal excision procedures has been reported as only 1.4% 
to 15% (McHenry et al., 1991; Shen et al., 2010; Takami et al., 2002) and the 5-year mortality 
rate ranges from 0.9% to 17% (Takami et al., 2002). To some, it therefore appears that there 
might be no real benefit for the patient to undergo more extensive surgery in presence of a 
clinically negative neck.  
4. Sentinel lymph nodes biopsy in thyroid cancer  
4.1 The middle ground in the controversy 
The lack of consensus on the matter of prophylactic CLND validates the need for a modality 
with which the surgeon can rely on to accurately predict the necessity for the procedure. 
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Accordingly, being able to identify those patients who would benefit from nodal dissection 
before a more extensive procedure is undertaken would improve PTC management (Anand 
et al., 2009). 
Preoperative ultrasound is unable to detect all metastatic lymph nodes in the central 
compartment of the neck (Roh & Koch, 2010) while intraoperative palpation and lymph 
node size assessment are not accurate predictors of lymph node status (Fukui et al., 2001). 
In this perspective, the SLNB is theoretically appealing for PTC since it could detect 
subclinical lymph node metastases, thereby allowing the formal CLND to be performed 
only in patients with documented lymph node metastases, thus avoiding the morbidity of 
CLND in a significant percentage of patients with node-negative disease. In other words, 
SLNB may be helpful in selecting patients who would benefit from CLND, thus reducing 
unnecessary surgery and possible morbidity in other patients (Roh & Koch, 2010; 
Sakorafas et al., 2010).  
The main advantage of an accurate SLNB technique would be the identification of node-
negative patients with thyroid cancer in whom an unnecessary prophylactic central node 
dissection could be avoided (Roh & Koch, 2010). It allows the surgeon to alter the surgical 
procedure in real time. Completing a central neck dissection at the time of initial surgery can 
also potentially avoid the higher complication rates that have been reported with 
reoperation in the central compartment. Another advantage of SLNB biopsy is that it may 
help identify, at the time of initial operation, patients who are likely to develop a 
challenging central compartment recurrence. The SLNB technique may also permit early 
detection of patients who may benefit from adjuvant radioactive iodine ablation (Anand et 
al., 2009; Roh & Koch, 2010). Alternatively, biopsies of sentinel lymph nodes may avoid the 
use of ablative 131I treatment in patients with low-risk thyroid cancers with SLNs that are 
negative for metastases. Furthermore, malignant Hürthle cell tumors and well-differentiated 
follicular carcinomas are difficult to identify histologically, and SLNB in such cases may aid 
in establishing the diagnoses if metastases can be identified in SLNs (Takami et al., 2002). 
In summary, the SLNB is an alternative approach that may guide the decision to proceed 
with formal lymphadenectomy. For this tool to be truly useful, it needs to accurately 
identify lymph node metastases, have a low false-negative rate and be associated with less 
morbidity than the formal CCND. SLNB for PTC has therefore been studied in several 
settings using different techniques; the sections that follow will review that data.  
4.2 The technique 
Since the introduction of the SLNB in PTC by Keleman (Keleman et al., 1998) several 
variations of the technique have been described. The variability resides mainly in the type of 
dye or isotope injected, the volume that was injected, the timing of injection, the site of 
injection and the subsequent assessment of the sentinel lymph node. Table 1 modified from 
the largest meta-analysis of SLNB in PTC, summarizes the techniques used in all the studies 
performed up to now on the topic (Balasubramanian & Harrison, 2011). 
Vital blue dyes are the most frequently injected medium with methylene blue, isosulphan 
blue and patent blue V being the most common types.  In general, methylene blue is found 
to be the least expensive and to generate less hypersensitivity reactions than the others. All 
of them, however, have been shown to have minimal reactivity except isosulfan blue. 
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Indeed, since rosaniline dyes are used in many commercially available products, including 
cosmetics, paper, and textiles, patients may be sensitized to isosulfan blue by previous 
exposure to apparently unrelated compounds. Moderate and severe allergic reactions, 
including anaphylaxis, have been reported in up to 2% of patients receiving isosulfan blue 
(Kelley and Holmes, 2011). All blue dye disappears during histologic processing and does 
not affect histologic analysis (Roh and Koh, 2010).  
In terms of radioisotopes, different forms of 99m-Technetium labeled colloids have been 
used. The sentinel lymph node in these cases is localized either by a marking on the skin 
overlying the lymph node; alternatively, it can be localized by radiotracer using a gamma-
probe intraoperatively.  
 
Reference n Population Dye/Isotope 
Volume 
injected 
(mL) 
Timing of 
injection 
Injection 
site 
Assessment 
of SLN 
Cunningham 
et al. 2010 
211 PTC 
1%isosulphan 
blue 
0.5-2 
After 
mobilization
IT FS and H 
Anand  
et al. 2009 
97 
Suspicious 
and PTC 
1% methylene 
blue 
0.2-0.3 
Before 
mobilization
PT H 
Takeyama  
et al. 2009 
37 
Suspicious 
and 
diagnostic 
1% sulphan 
blue 
0.1 
Before 
mobilization
PT FS and H 
Lee  
et al. 2009 
54 DTC 
2% methylene 
blue 
0.1-0.5 
Before 
mobilization
PT FS and H 
Bae  
et al. 2009 
11 PTC 
2% methylene 
blue 
0.5 
After strap 
muscle 
retraction 
IT FS and H 
Roh and 
Park, 2008 
50 PTC 
2% methylene 
blue 
0.2 
After strap 
muscle 
retraction 
PT FS and H 
Wang  
et al. 2008 
25 PTC 
2% methylene 
blue 
1-2 NA PT H 
Rubello  
et al. 2006 
153 PTC 
0.5% patent 
blue V 
0.25ml/c
m 
After strap 
muscle 
retraction 
IT FS and H 
Abdella 
2006 
30 
Benign 
nodules 
1% isosulphan 
blue 
0.5-1 
After strap 
muscle 
retraction 
IT H 
Peparini 
 et al. 2006 
9 PTC 
2.5% patent 
blue V 
0.1-0.2 NA PT or IT NA 
Falvo  
et al. 2006 
18 PTC Methylene blue 0.4 
After 
mobilization
IT H 
Dzodic  
et al. 2006 
40 DTC 
1% methylene 
blue 
0.2 
After strap 
muscle 
retraction 
PT FS and H 
www.intechopen.com
 
Updates in the Understanding and Management of Thyroid Cancer 
 
226 
Reference n Population Dye/Isotope 
Volume 
injected 
(mL) 
Timing of 
injection 
Injection 
site 
Assessment 
of SLN 
Chow  
et al. 2004 
15 PTC 
2.5% patent 
blue V 
0.5-1 
After strap 
muscle 
retraction 
IT H 
Takami  
et al. 2003 
68 PTC 
1% isosulphan 
blue 
0.3 
After strap 
muscle 
retraction 
PT FS and H 
Tsugawa  
et al. 2002 
38 PTC 
1% patent blue 
VF 
0.2-0.5 NA IT H 
Fukui  
et al. 2001 
22 PTC 
2% methylene 
blue 
0.1 
After 
mobilization
PT 
FS and H 
(but not 
all cases) 
Arch-Ferrer 
et al. 2001 
22 PTC 
1% isosulphan 
blue 
0.5 
After 
mobilization
IT H 
Catarci  
et al. 2001 
8 
Suspicious 
and PTC 
2.5% patent 
blue V 
0.2-0.4 
Before 
mobilization
IT H 
Dixon  
et al. 2000 
40 
Suspicious 
and DTC 
Isosulphan blue 0.1-0.7 
After strap 
muscle 
retraction 
IT FS and H 
Kelemen  
et al. 1998 
17 
Suspicious 
and DTC 
1% isosulphan 
blue 
0.1-0.8 
After strap 
muscle 
retraction 
IT FS and H 
Lee  
et al. 2009 
43 DTC 
99mTc-labelled 
tin colloid 
0.1-0.2 Preop US IT FS and H 
Boschin  
et al. 2008 
65 PTC 
99mTc-labelled 
nanocolloid 
0.1-0.2 Preop US IT FS and H 
Carcoforo  
et al. 2007 
64 
Suspicious 
and PTC 
99mTc-labelled 
nanocolloid 
0.3 Preop US PT H 
Stoecki  
et al. 2003 
10 
Suspicious 
and DTC 
99mTc-labelled 
sulphur colloid 
0.2 Preop US 
PT and 
later IT 
H 
Catarci  
et al. 2001 
8 
Suspicious 
and PTC 
99mTc-labelled 
colloidal 
albumin 
0.1 Preop US IT H 
Rettenbacher 
et al.  
2000 
9 
Suspicious 
and DTC 
99mTc-labelled 
nanocolloid 
0.5 NA IT H 
(Adapted from Balasubramanian & Harrison, 2011) 
Legend: SLN, sentinel lymph node; SLNB, sentinel lymph node biopsy; PTC, papillary thyroid cancer; 
IT, intratumoral; PT, peritumoral; FS, frozen section; H, histology; DTC, differentiated thyroid cancer; 
US, ultrasound; NA, data not available.  
Table 1. Characteristics of studies evaluating sentinel lymph node biopsy in thyroid surgery 
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We have found that the protocol currently used at our institution was easy to apply and had 
good outcomes (Figure 1). We therefore describe our technique in details. Following 
splitting of the strap muscles to expose the thyroid nodule, four quadrants around the 
tumor are injected with a total of 0.2cc’s of methylene blue with a tuberculin syringe. At this 
juncture, one minute without manipulation is set aside to allow for diffusion of the dye. The 
lymphatic channels which stain blue (tract of blue dye, Figure 2) are then followed into the 
central compartment and associated blue lymph nodes are harvested and sent for frozen 
section analysis (Figure 3). Thyroidectomy is then performed. If there are no blue lymph 
nodes identified, thyroidectomy is performed. In either case, re-examination of the central  
 
Fig. 1. Summary of the McGill Thyroid Injection Protocol 
 
Fig. 2. Technique of SLN biopsy. Moments after injection of methylene blue, a tract of blue 
dye is seen heading towards the central compartment and pooling inside the SLN. 
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compartment is performed after thyroidectomy and all blue nodes are sent for frozen 
section analysis. All frozen section samples are submitted for permanent analysis following 
intra-operative assessment. 
 
Fig. 3. The two lymph nodes above stained blue and were sent for frozen section analysis. 
4.3 Review of outcomes 
Keleman et al, in 1998, were the first to report the use of SLNB for thyroid carcinoma. 
Isosulfan blue dye was injected in 17 patients with thyroid neoplasms and the SLN was 
identified in 15 patients.   SLN detection was missed in 11.8% of patients due to retrosternal 
localized SLN’s and false-negative cases constituted 8%.  Haigh & Giuliano in 2000 
performed SLN biopsy in 17 cases and identified metastasis in 56% of cases.  Notably, a 
control neck dissection was not carried out in all patients in both of these studies, and as 
such, positive and negative predictive values could not be determined. In a recent study, 
Cunningham et al (2010) performed a retrospective review of 211 patients and concluded 
that SLNB is feasible, safe and can identify patients who may benefit from CCND.  As in the 
other previous studies, however, a CCND was not performed on all patients and thus a false 
negative rate could not be determined.   
Given its aim of identifying the patients who do not require CCND, the single most critical 
qualitative descriptor for SLNB is the false-negative rate (FNR). This requires comparison of 
SLNB to a gold standard for the identification of occult metastases. The gold standard used 
varies from study to study. Most frequently, a control neck dissection is performed in all 
cases with its extent going from central compartment neck dissection only to a formal 
modified lateral neck dissection passing through a localized dissection of non-sentinel 
lymph nodes above and bellow the omohyoid (Dzodic, 2006). Another study used 131I scan 
as the gold standard to help define the true-positive and true-negative SLN (Dixon et al., 
2008). 
Fukui et al conducted a study in 2001 on 22 patients with PTC who underwent a control 
lateral and central compartment neck dissection.  SLN’s were found in 21 of 22 patients 
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and the prediction of disease status was accurate in 19 of 21 patients (90%).  Two false 
negatives were reported in this study. Using peritumoral injection of blue dye, Takami et 
al (2002) reported a 12.5% SLN FNR in a prospective study of 68 patients. Similarly, Roh 
et al (2007) reported a 22% FNR using peritumoral blue dye in 50 patients. In 2009, Anand 
et al published the largest prospective series on SLN biopsy to date (N = 98) showing the 
reliability of SLN biopsy in the management of well differenciated thyroid cancer. The 
study showed with a sensitivity of 100% that a negative SLN on permanent pathological 
analysis represents a negative central compartment. The primary goal of this study was to 
determine if the SLN in WDTC was indeed a sensitive predictor of the status of the central 
compartment while avoiding the possible confounding affect of frozen section analysis. 
 For this reason frozen section analysis was not performed. In a recent study 
encompassing the largest series to date on the technique, frozen section analysis was 
employed to clarify its role in surgical practice. They studied a total of 157 patients 
injected with methylene blue. The sensitivity, specificity, positive predictive value and 
negative predictive value of the SLN biopsy technique to remove all disease from the 
central compartment was 92.9%, 100%, 100% and 98.8% respectively (p < 0.0001). This 
protocol would have eliminated the need for a CCND in 92% (144/157) in press 
(Richardson et al., in preparation). 
A systematic review and meta-analysis of SLNB in thyroid cancer was recently published 
and looked at all the possible outcomes with the use of this technique (Balasubramanian & 
Harrison, 2011). Twenty-four studies were included in the analysis and great heterogeneity 
in techniques, assessment methodology and extent of nodal surgery were noted. The overall 
detection rate of SLN was 86.3% (blue dye 83.7%, and radioisotope 98.4%). The combined 
use of blue dye and radioisotope reached a detection rate of 96%. Sentinel lymph nodes with 
evidence of metastasis were present in 42.9% of patients with PTC and an identified SLNB. 
Following this positive SLN biopsy, 60.5% of patients had additional lymph node 
metastases identified on the neck dissection. The FNR of the blue dye technique was 7.7% 
while the radioisotope technique had a FNR of 16%. The combined techniques FNR was 0%. 
This meta-analysis also evaluated the methods of assessment of SLNB. It demonstrated that 
in this context simple frozen section was unreliable since it had a FNR of 12% (i.e. the frozen 
section was negative but the final histopathology of the same lymph node was positive). 
However, with the use of intraoperative immunohistochemical staining such as 
anticytokeratin and antithyroglobulin antibody, additional cases could be adequately 
identified thereby decreasing the FNR. This analysis concluded that SNB in thyroid cancer is 
a promising technique that has the potential to avoid prophylactic lymph node surgery in 
up to 57% of patients with clinically node-negative thyroid cancer. However, at this stage 
the data is still inconsistent and there appears to be a need for a more rigorous assessment of 
the SLNB technique in thyroid cancer. 
4.4 Pitfalls of sentinel lymph node biopsy in papillary thyroid cancer 
4.4.1 The false-negative rate 
As described above, despite the more promising recent studies, FNRs as high as 22% have 
been reported and remain a serious concern regarding the value of SLNB (Sakorafas et al., 
2010). Others have demonstrated that falsely negative SLNB happen even in cases of grossly 
positive metastatic PTC in the neck and have hypothesized that this is possibly occurring 
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because the normal path of lymphatic drainage was blocked by tumor-laden lymphatics 
(Dixon et al., 2000). In addition to blockage of lymphatics by tumor, lymphatic disruption 
during exposure of thyroid nodule or gland mobilization could also account for the lack of 
identification of the otherwise positive lymph node. We therefore recommend minimal 
dissection prior to injection of the dye.  
It is also likely that the extensive lymphatic network in the neck complicates the practical 
application of the theoretical concept of SLNB in patients with thyroid cancer (Sakorafas et 
al., 2010). Noguchi et al., in 1987, demonstrated that up to 7% of thyroid metastases appear 
in the lateral compartment only, bypassing the central lymph nodes, which could explain 
the false-negative cases in studies limited to the central compartment.  
Furthermore, the concept of “SLN blind spot” was introduced by some authors to account 
for some of the false-negative cases. They describe three such cases where a blue node 
adherent to the substance of the thyroid gland was found ex vivo by the pathologist, and 
might have not been found intraoperatively because the blue-stained thyroid gland masked 
the blue tract and blue node (Cunningham et al., 2010). 
Given that lymph nodes harboring metastatic disease can be as small as 3 mm, the problem 
of a “crushed node” or a sample small enough that it may sacrifice permanent section has 
been reported. A pathologist with expertise in head and neck oncology, namely thyroid 
cancer, is therefore desirable for assessing the frozen section samples (Amir et al., 2011). 
The lack of an approach toward multifocal disease is potentially another cause of false 
negatives. Indeed, while the dominant nodule may have been malignant, a non-dominant 
nodule also harboring disease that was not injected with methylene blue may be the source 
of the metastasis that is therefore missed because the nodule was not injected (Amir et al., 
2011). Future studies designed to develop a novel approach to multifocal disease would 
therefore be very pertinent. 
4.4.2 Adverse events related to sentinel node biopsy 
In addition to the complications associated with a CCND that can follow a positive SLNB, 
the procedure of the SLNB has in itself been associated with some adverse events. From 
experience, we have noted that during injection, spillage of the dye may cause problems 
in identification of the sentinel lymph node, recurrent laryngeal nerve and parathyroid 
glands. This can, however, be easily overcome by slow intratumoral or peritumoral dye 
injection and immediate blotting of spillage at the injection site. One study has reported 
permanent hypoparathyroidism secondary to removal of a parathyroid gland that has 
stained blue (Cunningham et al., 2010). All degrees of skin responses to the blue dye have 
also been reported. For instance, methylene blue, despite its safety record, has been 
associated with intense erythema, superficial ulceration, and on one occasion a necrotic 
lesion (Kelley & Holmes 2011). Methylene blue-induced skin necrosis results from 
oxidation of surrounding tissues causing breakdown of cell membranes and 
inflammation, as well as a local vasoconstrictive effect due to methylene blue’s inhibitory 
effect on nitric oxide. There is no increase in recurrent laryngeal injury rates associated 
with SLNB (Roh & Koch, 2010). 
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5. Conclusion  
The management of occult cervical lymph node metastasis in WDTC is controversial. The 
SLNB is a safe and accurate method for assessing the possible involvement of the cervical 
lymph nodes by a primary thyroid tumour which allows for intraoperative decision making 
regarding the extent of neck dissection needed in each case. Despite the promising data, it 
might be too early to consider the SLNB technique as a standard of care in the management 
of patients with thyroid cancer. Several technicalities and pitfalls still need to be addressed. 
Most importantly, at this point, randomized controlled clinical trials are necessary to 
determine whether occult nodal metastases play a clinically significant role in longterm 
survival and disease-free survival, and whether SLNB and subsequent nodal management is 
associated with a survival benefit in patients with thyroid cancer. 
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